Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
14 mai 2024 08h00 HE
|
Candel Therapeutics
Announced positive survival data from ongoing randomized phase 2 clinical trial of CAN-2409 in borderline resectable pancreatic cancerPhase 2 topline overall survival data for CAN-2409 in non-small...
Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting
25 avr. 2024 08h00 HE
|
Candel Therapeutics
NEEDHAM, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal...
Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
11 avr. 2024 09h00 HE
|
Candel Therapeutics
NEEDHAM, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal...
Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors
09 avr. 2024 08h00 HE
|
Candel Therapeutics
First-in-class multimodal immunotherapy candidate, for induction of tertiary lymphoid structures, being developed as a novel therapeutic strategy for solid tumors from the enLIGHTEN™ Discovery...
Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
04 avr. 2024 08h00 HE
|
Candel Therapeutics
Updated positive interim data showed notable improvements in estimated median overall survival of 28.8 months after experimental treatment with CAN-2409 versus only 12.5 months in control group in...
Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma
28 mars 2024 16h05 HE
|
Candel Therapeutics
The first cohort of patients were treated with multiple injections of CAN-3110 in the ongoing phase 1b clinical trial.The serial procedures were well tolerated without observed dose-limiting...
Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights
28 mars 2024 08h05 HE
|
Candel Therapeutics
On track for topline data from CAN-2409 phase 3 in localized intermediate/high risk prostate cancer, expected in Q4 2024Results from ongoing, first-in-human, phase 1b clinical trial of CAN-3110, in...
Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate
05 mars 2024 16h30 HE
|
Candel Therapeutics
NEEDHAM, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal...
CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma
13 févr. 2024 07h30 HE
|
Candel Therapeutics
NEEDHAM, Mass., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal...
Candel Therapeutics Sets Path to Success: Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and Catalysts
05 févr. 2024 08h00 HE
|
Candel Therapeutics
Candel Therapeutics Sets Path to Success: Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and Catalysts